Piper Sandler analyst Matt O’Brien raised the firm’s price target on Boston Scientific (BSX) to $115 from $95 and keeps an Overweight rating on the shares following the recent key opinion leader check. The firm consistent positive commentary and growth durability for several of Boston Scientific’s top-line growth drivers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific (BSX) Q4 Earnings Cheat Sheet
- Boston Scientific price target raised to $119 from $101 at Raymond James
- Boston Scientific price target raised to $111 from $86 at Barclays
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Boston Scientific announces data supporting use of FARAPULSE PFA system